Почетна › Склеродерма › Kalifornija
Kliničke studije za Склеродерма u državi Kalifornija
12 studija za Склеродерма traži učesnike na lokacijama u državi Kalifornija.
Gradovi u državi Kalifornija
Zvanični tekst studije (na engleskom)
Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO
- University of California Davis Comprehensive Cancer Center, Sacramento
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT03816345A Study of AZD0120 in Autoimmune Diseases
- Research Site, Duarte
- Research Site, Stanford
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 10. 11. 2026. · NCT07295847A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
- Loma Linda University Medical Center, Loma Linda
Тражи се учесникФаза 1
Узраст од 18 до 74 · Оба пола · Ажурирано 2. 11. 2026. · NCT07085104A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
- Nkarta Investigational Site, Los Angeles
Тражи се учесникФаза 1/2
Узраст од 18 до 75 · Оба пола · Ажурирано 30. 10. 2026. · NCT06733935A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
- UC San Diego Health, La Jolla
- Stanford University Medical Center, Redwood City
Тражи се учесникФаза 1
Узраст од 18 до 70 · Оба пола · Ажурирано 26. 10. 2026. · NCT06925542A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
- University of California Los Angeles, Los Angeles
- Paradigm Clinical Research - San Diego, San Diego
- Stanford University School of Medicine, Stanford
- и још 1
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 14. 10. 2026. · NCT07497087A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- GSK Investigational Site, Los Angeles
- и још 1
Тражи се учесникФаза 2/3
Узраст 18 и старији · Оба пола · Ажурирано 8. 9. 2026. · NCT05878717FT839 in Autoimmune Diseases
- Providence Medical Foundation, Fullerton
Тражи се учесникФаза 1/2
Узраст од 18 до 70 · Оба пола · Ажурирано 2. 9. 2026. · NCT07800871Platform Clinical Study for Conquering Scleroderma
- Keck School of Medicine at USC Medical Center, Los Angeles
- Cedars-Sinai Medical Center, Los Angeles
- Stanford University Medical Center, Palo Alto
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT06195072AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
- Artiva Investigational Site Chula Vista, Chula Vista
- Artiva Investigational Site Covina, Covina
- Artiva Investigational Site Los Alamitos, Los Alamitos
- и још 3
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 31. 7. 2026. · NCT06991114A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
- Wallace Rheumatic Center, Beverly Hills
- Providence Medical Foundation, Fullerton
- University of California Irvine, Irvine
- и још 2
Тражи се учесникФаза 1
Узраст од 12 до 70 · Оба пола · Ажурирано 22. 5. 2026. · NCT06308978Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)
- aTyr Investigative Site, Los Angeles
- aTyr Investigative Site, San Diego
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 7. 5. 2025. · NCT05892614Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.